Jean-Michel Molina

Best Publications

• HLA-B*5701 Screening for Hypersensitivity to Abacavir

  Simon Mallal;Elizabeth Phillips;Giampiero Carosi;Jean-Michel Molina

  2179
  Citations

• On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

  Abstr Act;C. Capitant;B. Spire;G. Pialoux

  1905
  Citations

• No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.

  J.M. Molina;C. Delaugerre;J. Le Goff;B. Mela-Lima

  883
  Citations

• Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

  Paul E Sax;David Wohl;Michael T Yin;Frank Post

  754
  Citations

• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

  Michael S. Saag;Constance A. Benson;Rajesh T. Gandhi;Jennifer F. Hoy

  713
  Citations

• Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

  Jean-Michel Molina;Jaime Andrade-Villanueva;Juan Echevarria;Ploenchan Chetchotisakd

  681
  Citations

• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

  Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  666
  Citations

• Hematopoietic growth factors. Biology and clinical applications.

  J E Groopman;J M Molina;D T Scadden

  647
  Citations

• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.

  Unknown

  632
  Citations

• Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

  Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  529
  Citations

• Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

  Jean-Michel Molina;Jean-Michel Molina;Isabelle Charreau;Bruno Spire;Laurent Cotte

  517
  Citations

• Tenofovir-Related Nephrotoxicity in Human Immunodeficiency Virus-Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus

  Alexandre Karras;Matthieu Lafaurie;André Furco;Anne Bourgarit

  478
  Citations

• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

  Michael S. Saag;Rajesh T. Gandhi;Jennifer F. Hoy;Raphael J. Landovitz

  472
  Citations

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

  Edwin DeJesus;Jürgen K. Rockstroh;Keith Henry;Jean Michel Molina

  454
  Citations

• Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment

  Yves Levy;Christine Lacabaratz;Laurence Weiss;Jean-Paul Viard

  444
  Citations

• Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

  Kenneth H Mayer;Kenneth H Mayer;Jean-Michel Molina;Melanie A Thompson;Peter L Anderson

  430
  Citations

• Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

  Jean-Michel Molina;Isabelle Charreau;Christian Chidiac;Gilles Pialoux

  429
  Citations

• Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

  Unknown

  428
  Citations

• Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

  Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  416
  Citations

• Prognostic Factors and Outcome of Human Herpesvirus 8–Associated Primary Effusion Lymphoma in Patients With AIDS

  Emmanuelle Boulanger;Laurence Gérard;Jean Gabarre;Jean-Michel Molina

  370
  Citations